Kibow – Dietary Supplements for Uremic and Metabolic Syndrome --

Pioneering products for uremic and metabolic syndromes

FAQ

Press Releases

Date		Title
FEB/25/08		Kibow Biotech, Inc. and Vétoquinol S.A. expand their veterinary licensing and marketing agreement for worldwide applications
JAN/14/08		Kibow Biotech obtains Australian, Chinese and Indian patents protecting the composition and basic technology behind its oral probiotic formulation for chronic kidney failure
NOV/14/07		Kibow Biotech Enters US Consumer Dietary Supplement Market with Kibow Flora™ and Three Related Products Targeting the Risk Factors of Metabolic Syndrome
JUL/16/07		Kibow Biotech Launches Limited Human Clinical Trial in North America of its Probiotic, Kibow Biotics^®, in Kidney Failure
JUN/01/07		Kibow Biotics^® probiotic formulation for kidney failure to be discussed at ASAIO 2007 Click to view Dr. Eli Friedman’s discussion on using the gut as an artificial kidney
MAY/28/06		Kibow Biotech, Inc. Announces a Licensing Agreement of its "Enteric Dialysis™" Technology and "Kibow Biotics^®" Product Formulation to Vetoquinol USA, Inc.
NOV/01/05		Kibow Biotech to Participate and Exhibit at Forthcoming American Society of Nephrology Annual Meeting in Philadelphia, Nov. 10-12
JAN/27/05		Kibow Biotech, Inc. to Present at Medtech Insight's "Investment In Innovation" Conference
MAR/29/04		Kibow Biotech, Inc. Secures First Two US Patents for Gut-Based Uremia Therapy Products Targeting Kidney Patient
JUL/15/02		Kibow Biotech, Inc. Awarded $993,826 in Second Fast-Track Phase I and II Small Business Innovative Research (SBIR) Grant